Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Net Income (2019 - 2025)

Eton Pharmaceuticals' Net Income history spans 7 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Net Income fell 407.34% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$6.7 million, down 21.91%, while the annual FY2024 figure was -$3.8 million, 308.44% down from the prior year.
  • Net Income for Q3 2025 was -$1.9 million at Eton Pharmaceuticals, up from -$2.6 million in the prior quarter.
  • Across five years, Net Income topped out at $5.1 million in Q1 2021 and bottomed at -$6.1 million in Q3 2021.
  • The 5-year median for Net Income is -$1.6 million (2025), against an average of -$1.1 million.
  • The largest annual shift saw Net Income surged 392.62% in 2023 before it plummeted 407.34% in 2025.
  • A 5-year view of Net Income shows it stood at $1.0 million in 2021, then fell by 12.22% to $912000.0 in 2022, then tumbled by 347.37% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then crashed by 222.24% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Net Income are -$1.9 million (Q3 2025), -$2.6 million (Q2 2025), and -$1.6 million (Q1 2025).